Published in Nat Rev Cancer on November 15, 2012
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med (2013) 8.89
Necroptosis and its role in inflammation. Nature (2015) 3.01
Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ (2014) 2.66
To be or not to be? How selective autophagy and cell death govern cell fate. Cell (2014) 2.63
Apoptotic cell clearance: basic biology and therapeutic potential. Nat Rev Immunol (2014) 2.59
Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology (2014) 2.30
Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation. Blood (2014) 2.01
HMGB1 in health and disease. Mol Aspects Med (2014) 1.67
Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer (2013) 1.64
Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ (2013) 1.64
Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol (2014) 1.57
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
The Basis of Oncoimmunology. Cell (2016) 1.47
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer (2015) 1.43
Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther (2013) 1.41
Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ (2013) 1.39
Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology (2013) 1.35
An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy. Oncoimmunology (2014) 1.35
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2013) 1.31
Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31
Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. Oncoimmunology (2014) 1.30
Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity. Front Oncol (2014) 1.29
Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol (2016) 1.26
Emerging strategies to effectively target autophagy in cancer. Oncogene (2015) 1.26
Strange attractors: DAMPs and autophagy link tumor cell death and immunity. Cell Death Dis (2013) 1.25
Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ (2013) 1.25
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology (2014) 1.22
Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling. J Biol Chem (2013) 1.22
Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity. Front Immunol (2013) 1.22
The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev (2015) 1.22
Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment. Cell (2016) 1.21
Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions. Clin Cancer Res (2015) 1.15
Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood (2014) 1.15
TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy. Cancer Res (2013) 1.14
Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. Cell Death Differ (2013) 1.13
Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology (2015) 1.13
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Front Immunol (2015) 1.12
Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ (2013) 1.12
Many faces of DAMPs in cancer therapy. Cell Death Dis (2013) 1.11
DAMPs from Cell Death to New Life. Front Immunol (2015) 1.11
Emerging functions of the unfolded protein response in immunity. Nat Immunol (2014) 1.10
Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer (2016) 1.08
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology (2015) 1.07
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology (2015) 1.06
RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells. Cell Death Differ (2014) 1.05
Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. Oncotarget (2015) 1.05
Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. Oncoimmunology (2014) 1.04
Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology (2015) 1.02
Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. Mol Ther (2013) 1.02
A critical role for human caspase-4 in endotoxin sensitivity. J Immunol (2014) 1.01
Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res (2013) 1.01
Autophagy in inflammation, infection, neurodegeneration and cancer. Int Immunopharmacol (2013) 1.00
Combinatorial strategies for the induction of immunogenic cell death. Front Immunol (2015) 0.98
The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. Autophagy (2016) 0.97
Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget (2015) 0.96
Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology (2014) 0.96
The regulatory role of invariant NKT cells in tumor immunity. Cancer Immunol Res (2015) 0.96
Pattern-recognition receptors and gastric cancer. Front Immunol (2014) 0.95
Anticancer drugs for the modulation of endoplasmic reticulum stress and oxidative stress. Tumour Biol (2015) 0.94
TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells. Cell Mol Immunol (2013) 0.93
Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications. Front Immunol (2015) 0.92
Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunology (2014) 0.91
Antitumor Virotherapy by Attenuated Measles Virus (MV). Biology (Basel) (2013) 0.91
Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models. Front Immunol (2015) 0.91
Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. Cancers (Basel) (2015) 0.90
Therapeutic applications of herbal medicines for cancer patients. Evid Based Complement Alternat Med (2013) 0.90
Rose Bengal acetate photodynamic therapy (RBAc-PDT) induces exposure and release of Damage-Associated Molecular Patterns (DAMPs) in human HeLa cells. PLoS One (2014) 0.90
Rewiring cancer cell death to enhance oncolytic viro-immunotherapy. Oncoimmunology (2013) 0.90
Overview of current immunotherapeutic strategies for glioma. Immunotherapy (2015) 0.89
DAMPs activating innate and adaptive immune responses in COPD. Mucosal Immunol (2013) 0.89
Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Front Immunol (2015) 0.89
Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation. Oncoimmunology (2013) 0.89
Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies. Cancer Metastasis Rev (2015) 0.89
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. World J Gastroenterol (2014) 0.88
Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood (2016) 0.86
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. Oncoimmunology (2015) 0.85
Mouse models in oncoimmunology. Nat Rev Cancer (2016) 0.85
Mitochondrial reactive oxygen species regulate the strength of inhibitory GABA-mediated synaptic transmission. Nat Commun (2014) 0.85
Mechanisms of therapeutic resistance in cancer (stem) cells with emphasis on thyroid cancer cells. Front Endocrinol (Lausanne) (2014) 0.85
Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma. Oncoimmunology (2015) 0.85
High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers. Virchows Arch (2015) 0.84
Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. Oncoimmunology (2016) 0.84
Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy. Oncoimmunology (2013) 0.84
Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology (2016) 0.84
The ever-expanding immunomodulatory role of calreticulin in cancer immunity. Front Oncol (2015) 0.83
The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells. Oncotarget (2015) 0.83
Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice. Cancer Immunol Immunother (2014) 0.83
Therapeutic implications of immunogenic cell death in human cancer. Front Immunol (2014) 0.83
Autophagy proteins regulate cell engulfment mechanisms that participate in cancer. Semin Cancer Biol (2013) 0.83
Enhancement of Anti-Inflammatory Activity of Curcumin Using Phosphatidylserine-Containing Nanoparticles in Cultured Macrophages. Int J Mol Sci (2016) 0.83
Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology (2015) 0.83
Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer. Oncotarget (2016) 0.82
Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation. Cell Death Differ (2016) 0.82
The progression of cell death affects the rejection of allogeneic tumors in immune-competent mice - implications for cancer therapy. Front Immunol (2014) 0.82
Killing cancer cells, twice with one shot. Cell Death Differ (2014) 0.82
Withania somnifera Induces Cytotoxic and Cytostatic Effects on Human T Leukemia Cells. Toxins (Basel) (2016) 0.82
The oncolytic peptide LTX-315 triggers immunogenic cell death. Cell Death Dis (2016) 0.82
Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology (2016) 0.81
Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No? J Cancer (2015) 0.81
Oncolytic viruses as immunotherapy: progress and remaining challenges. Onco Targets Ther (2016) 0.81
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Immunity, inflammation, and cancer. Cell (2010) 28.27
The clonal evolution of tumor cell populations. Science (1976) 24.39
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature (2002) 19.77
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
The mammalian unfolded protein response. Annu Rev Biochem (2005) 16.31
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 14.94
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature (2010) 11.24
Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell (2010) 10.96
Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med (1995) 10.91
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
PI3K pathway alterations in cancer: variations on a theme. Oncogene (2008) 9.94
Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev (2004) 9.28
Molecular identification of a danger signal that alerts the immune system to dying cells. Nature (2003) 8.90
The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol (2012) 8.52
High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med (2000) 7.38
Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science (1997) 7.31
Immunosuppressive effects of apoptotic cells. Nature (1997) 7.03
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature (2000) 6.70
Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol (2006) 6.13
Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell (2005) 5.90
Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev (2005) 5.69
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62
High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol (2005) 5.04
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature (2009) 4.98
Endogenous HMGB1 regulates autophagy. J Cell Biol (2010) 4.71
Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity (2009) 4.49
mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem (2004) 4.43
Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity (2008) 4.37
Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32
A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A (2006) 4.25
Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature (2010) 4.10
Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci U S A (2009) 3.99
Pattern recognition receptors and control of adaptive immunity. Immunol Rev (2009) 3.91
TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J Exp Med (2008) 3.62
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol (2012) 3.57
The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance. Purinergic Signal (2006) 3.52
Decoding cell death signals in inflammation and immunity. Cell (2010) 3.41
Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity. Nature (2011) 3.37
Endoplasmic reticulum stress responses. Cell Mol Life Sci (2008) 3.11
HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep (2004) 3.00
Systemic effects of local radiotherapy. Lancet Oncol (2009) 2.97
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96
The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol (2006) 2.90
Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res (2011) 2.89
Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med (2012) 2.89
The inflammatory response to cell death. Annu Rev Pathol (2008) 2.85
Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem (2003) 2.80
Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med (2012) 2.79
Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells. EMBO J (1995) 2.78
Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol (2004) 2.75
Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene (2009) 2.74
F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity (2012) 2.72
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer (2012) 2.71
Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med (2010) 2.62
Extracellular adenosine triphosphate and adenosine in cancer. Oncogene (2010) 2.53
Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One (2008) 2.51
Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J (2009) 2.48
Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways. Immunity (2011) 2.47
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J (2012) 2.45
Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res (2010) 2.29
Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res (2004) 2.24
Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis (2006) 2.20
Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer (2004) 2.20
NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood (2005) 2.15
Cutting edge: critical role for mesothelial cells in necrosis-induced inflammation through the recognition of IL-1 alpha released from dying cells. J Immunol (2008) 2.13
Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta (2009) 2.07
Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med (2004) 2.06
Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol (2011) 2.05
Mitochondrial N-formylmethionyl proteins as chemoattractants for neutrophils. J Exp Med (1982) 2.04
Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest (2010) 2.02
The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ (2008) 2.01
Inhibitory effects of apoptotic cell ingestion upon endotoxin-driven myeloid dendritic cell maturation. J Immunol (2002) 2.01
Endogenous histones function as alarmins in sterile inflammatory liver injury through Toll-like receptor 9 in mice. Hepatology (2011) 1.94
Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther (2007) 1.90
Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res (2007) 1.86
Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther (2004) 1.84
Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ (2008) 1.84
Chemotherapy induces ATP release from tumor cells. Cell Cycle (2009) 1.83
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev (2011) 1.76
Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene (2010) 1.75
Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res (2010) 1.74
Targeting ER stress induced apoptosis and inflammation in cancer. Cancer Lett (2010) 1.71
RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr Mol Med (2007) 1.66
Caspase-8 deficiency facilitates cellular transformation in vitro. Cell Death Differ (2008) 1.64
Cyclophilin A is a damage-associated molecular pattern molecule that mediates acetaminophen-induced liver injury. J Immunol (2011) 1.63
Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med (2012) 1.63
Modulating stress responses by the UPRosome: a matter of life and death. Trends Biochem Sci (2011) 1.62
Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res (2011) 1.62
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. Nat Immunol (2006) 10.55
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature (2006) 9.77
Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity (2007) 6.75
Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity (2009) 4.49
RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. Immunity (2011) 3.53
Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity (2013) 3.22
Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. Biochim Biophys Acta (2006) 3.12
RIP kinases at the crossroads of cell death and survival. Cell (2009) 3.04
Apoptosis and necrosis: detection, discrimination and phagocytosis. Methods (2008) 2.93
Caspase-14 protects against epidermal UVB photodamage and water loss. Nat Cell Biol (2007) 2.82
Neutrophil extracellular trap cell death requires both autophagy and superoxide generation. Cell Res (2010) 2.82
Toxic proteins released from mitochondria in cell death. Oncogene (2004) 2.78
Targeted peptidecentric proteomics reveals caspase-7 as a substrate of the caspase-1 inflammasomes. Mol Cell Proteomics (2008) 2.64
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J (2012) 2.45
Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta (2007) 2.31
Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis (2006) 2.20
Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta (2009) 2.07
Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol (2011) 2.05
Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A (2012) 1.97
Inflammation-associated enterotypes, host genotype, cage and inter-individual effects drive gut microbiota variation in common laboratory mice. Genome Biol (2013) 1.97
Caspase-14 is required for filaggrin degradation to natural moisturizing factors in the skin. J Invest Dermatol (2011) 1.93
The Nod-like receptor family member Naip5/Birc1e restricts Legionella pneumophila growth independently of caspase-1 activation. J Immunol (2007) 1.89
Linking ER Stress to Autophagy: Potential Implications for Cancer Therapy. Int J Cell Biol (2010) 1.86
Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. Sci Signal (2012) 1.82
Characterization of counterfeit artesunate antimalarial tablets from southeast Asia. Am J Trop Med Hyg (2006) 1.79
Major cell death pathways at a glance. Microbes Infect (2009) 1.77
Targeting ER stress induced apoptosis and inflammation in cancer. Cancer Lett (2010) 1.71
Targeting Rac1 by the Yersinia effector protein YopE inhibits caspase-1-mediated maturation and release of interleukin-1beta. J Biol Chem (2004) 1.70
Simultaneous targeting of IL-1 and IL-18 is required for protection against inflammatory and septic shock. Am J Respir Crit Care Med (2014) 1.68
Beclin1: a role in membrane dynamics and beyond. Autophagy (2012) 1.68
ROS-mediated mechanisms of autophagy stimulation and their relevance in cancer therapy. Autophagy (2010) 1.68
Autophagy: for better or for worse. Cell Res (2011) 1.65
The emerging roles of serine protease cascades in the epidermis. Trends Biochem Sci (2009) 1.64
Molecular mechanisms and pathophysiology of necrotic cell death. Curr Mol Med (2008) 1.63
TNFR1- and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury. FASEB J (2005) 1.60
Programmed necrosis from molecules to health and disease. Int Rev Cell Mol Biol (2011) 1.58
Are metacaspases caspases? J Cell Biol (2007) 1.57
ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. Autophagy (2013) 1.55
Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericin-mediated photodynamic therapy. FASEB J (2006) 1.53
Autophagy: shaping the tumor microenvironment and therapeutic response. Trends Mol Med (2013) 1.52
Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother (2011) 1.51
Caspase-14 reveals its secrets. J Cell Biol (2008) 1.47
Phagocytosis of necrotic cells by macrophages is phosphatidylserine dependent and does not induce inflammatory cytokine production. Mol Biol Cell (2003) 1.47
Disruption of HSP90 function reverts tumor necrosis factor-induced necrosis to apoptosis. J Biol Chem (2002) 1.45
Tumor necrosis factor-mediated cell death: to break or to burst, that's the question. Cell Mol Life Sci (2010) 1.44
Mitochondrial intermembrane proteins in cell death. Biochem Biophys Res Commun (2003) 1.44
ER stress-induced inflammation: does it aid or impede disease progression? Trends Mol Med (2012) 1.41
Laser ablation-inductively coupled plasma mass spectrometry for the characterization of pigments in prehistoric rock art. Anal Chem (2007) 1.38
Assessing autophagy in the context of photodynamic therapy. Autophagy (2010) 1.37
The unfolded protein response at the crossroads of cellular life and death during endoplasmic reticulum stress. Biol Cell (2012) 1.35
The death-fold superfamily of homotypic interaction motifs. Trends Biochem Sci (2011) 1.35
Proteome-wide Identification of HtrA2/Omi Substrates. J Proteome Res (2007) 1.34
SitePredicting the cleavage of proteinase substrates. Trends Biochem Sci (2009) 1.29
Differential signaling to apoptotic and necrotic cell death by Fas-associated death domain protein FADD. J Biol Chem (2003) 1.28
NOD-like receptors and the innate immune system: coping with danger, damage and death. Cytokine Growth Factor Rev (2011) 1.28
Proteome-wide substrate analysis indicates substrate exclusion as a mechanism to generate caspase-7 versus caspase-3 specificity. Mol Cell Proteomics (2009) 1.27
Autophagy in disease: a double-edged sword with therapeutic potential. Clin Sci (Lond) (2009) 1.26
Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev (2013) 1.24
Cell death in the skin. Apoptosis (2009) 1.22
Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis (2010) 1.22
INCA, a novel human caspase recruitment domain protein that inhibits interleukin-1beta generation. J Biol Chem (2004) 1.20
Acute modulations in permeability barrier function regulate epidermal cornification: role of caspase-14 and the protease-activated receptor type 2. Am J Pathol (2007) 1.20
DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown. Photochem Photobiol Sci (2011) 1.20
Depletion of Beclin-1 due to proteolytic cleavage by caspases in the Alzheimer's disease brain. Neurobiol Dis (2010) 1.17
Regulation of the expression and processing of caspase-12. J Cell Biol (2003) 1.16
Ultraviolet radiation-induced apoptosis in keratinocytes: on the role of cytosolic factors. Biochim Biophys Acta (2005) 1.16
Ins(1,4,5)P3 receptor-mediated Ca2+ signaling and autophagy induction are interrelated. Autophagy (2011) 1.16
Autophagy pathways activated in response to PDT contribute to cell resistance against ROS damage. J Cell Mol Med (2010) 1.16
Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int J Cancer (2014) 1.16
Up-regulation of cyclooxygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells. J Biol Chem (2003) 1.14
Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein response. Cancer Res (2009) 1.14
Methods for distinguishing apoptotic from necrotic cells and measuring their clearance. Methods Enzymol (2008) 1.13
NLRP3/caspase-1-independent IL-1beta production mediates diesel exhaust particle-induced pulmonary inflammation. J Immunol (2011) 1.13
Tumor necrosis factor-alpha-induced activation of RhoA in airway smooth muscle cells: role in the Ca2+ sensitization of myosin light chain20 phosphorylation. Mol Pharmacol (2003) 1.12
Activation of p38 MAPK is required for Bax translocation to mitochondria, cytochrome c release and apoptosis induced by UVB irradiation in human keratinocytes. FASEB J (2004) 1.12
Caspase-1 activates nuclear factor of the kappa-enhancer in B cells independently of its enzymatic activity. J Biol Chem (2004) 1.12
Differential activation of nuclear factor-kappaB by tumour necrosis factor receptor subtypes. TNFR1 predominates whereas TNFR2 activates transcription poorly. FEBS Lett (2002) 1.10
Determination of apoptotic and necrotic cell death in vitro and in vivo. Methods (2013) 1.08